The epidermal growth factor receptor (EGFR) contributes to tumor malignancy through gene amplification and/or protein overexpression. In our previous study, we developed an anti-human EGFR (hEGFR) monoclonal antibody, clone EMab-134 (mouse IgG1, kappa), which specifically detects both hEGFR and dog EGFR (dEGFR). The defucosylated mouse IgG2a version of EMab-134 (134-mG2a-f) exhibits antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) in dEGFR-overexpressed Chinese hamster ovary-K1 (CHO/dEGFR) cells and antitumor activities in mouse xenografts of CHO/dEGFR cells. In this study, the reactivity of 134-mG2a-f against a canine mammary gland tumor cell line (SNP) was examined by flow cytometry and immunocytochemistry. Furthermore, 134-mG2a-f highly exerted ADCC and CDC for SNP. The administration of 134-mG2a-f significantly suppressed the SNP xenograft growth. These results suggest that 134-mG2a-f exerts antitumor effects against dEGFR-expressing canine mammary gland tumors, and could be valuable as part of an antibody treatment regimen for them.
Get full access to this article
View all access options for this article.
References
1.
SungH, FerlayJ, SiegelRL, LaversanneM, SoerjomataramI, JemalA, and BrayF: Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2021; 71:209–249.
2.
TorreLA, IslamiF, SiegelRL, WardEM, and JemalA: Global cancer in women: Burden and trends. Cancer Epidemiol Biomarkers Prev, 2017; 26:444–457.
3.
GordonI, PaoloniM, MazckoC, and KhannaC: The Comparative Oncology Trials Consortium: Using spontaneously occurring cancers in dogs to inform the cancer drug development pathway. PLoS Med, 2009; 6:e1000161.
4.
GraimK, GorenshteynD, RobinsonDG, CarrieroNJ, CahillJA, ChakrabartiR, GoldschmidtMH, DurhamAC, FunkJ, StoreyJD, KristensenVN, TheesfeldCL, SorenmoKU, and TroyanskayaOG: Modeling molecular development of breast cancer in canine mammary tumors. Genome Res, 2020; 31:337–347.
5.
KabirFML, DeInnocentesP, AgarwalP, MillCP, Riese NdDJ, and BirdRC: Estrogen receptor-α, progesterone receptor, and c-erbB/HER-family receptor mRNA detection and phenotype analysis in spontaneous canine models of breast cancer. J Vet Sci, 2017; 18:149–158.
6.
RowellJL, McCarthyDO, and AlvarezCE: Dog models of naturally occurring cancer. Trends Mol Med, 2011; 17:380–388.
7.
PaoloniM, and KhannaC: Translation of new cancer treatments from pet dogs to humans. Nat Rev Cancer, 2008; 8:147–156.
8.
SorenmoKU, KristiansenVM, CofoneMA, ShoferFS, BreenAM, LangelandM, MongilCM, GrondahlAM, TeigeJ, and GoldschmidtMH: Canine mammary gland tumours; a histological continuum from benign to malignant; clinical and histopathological evidence. Vet Comp Oncol, 2009; 7:162–172.
9.
BorgeKS, NordS, Van LooP, LingjærdeOC, GunnesG, AlnæsGI, SolvangHK, LüdersT, KristensenVN, Børresen-DaleAL, and LingaasF: Canine mammary tumours are affected by frequent copy number aberrations, including amplification of MYC and loss of PTEN. PLoS One, 2015; 10:e0126371.
10.
SetoguchiA, SakaiT, OkudaM, MinehataK, YazawaM, IshizakaT, WatariT, NishimuraR, SasakiN, HasegawaA, and TsujimotoH: Aberrations of the p53 tumor suppressor gene in various tumors in dogs. Am J Vet Res, 2001; 62:433–439.
11.
HagaS, NakayamaM, TatsumiK, MaedaM, ImaiS, UmesakoS, YamamotoH, HilgersJ, and SarkarNH: Overexpression of the p53 gene product in canine mammary tumors. Oncol Rep, 2001; 8:1215–1219.
12.
LiuD, XiongH, EllisAE, NorthrupNC, RodriguezCOJr., O'ReganRM, DaltonS, and ZhaoS: Molecular homology and difference between spontaneous canine mammary cancer and human breast cancer. Cancer Res, 2014; 74:5045–5056.
13.
SchiffmanJD, and BreenM: Comparative oncology: What dogs and other species can teach us about humans with cancer. Philos Trans R Soc Lond B Biol Sci, 2015; 370.
14.
KhannaC, LondonC, VailD, MazckoC, and HirschfeldS: Guiding the optimal translation of new cancer treatments from canine to human cancer patients. Clin Cancer Res, 2009; 15:5671–5677.
15.
MaekawaN, KonnaiS, NishimuraM, KagawaY, TakagiS, HosoyaK, OhtaH, KimS, OkagawaT, IzumiY, DeguchiT, KatoY, YamamotoS, YamamotoK, TodaM, NakajimaC, SuzukiY, MurataS, and OhashiK: PD-L1 immunohistochemistry for canine cancers and clinical benefit of anti-PD-L1 antibody in dogs with pulmonary metastatic oral malignant melanoma. NPJ Precis Oncol, 2021; 5:10.
16.
UribeML, MarroccoI, and YardenY: EGFR in cancer: Signaling mechanisms, drugs, and acquired resistance. Cancers (Basel), 2021; 13:2748.
17.
YewaleC, BaradiaD, VhoraI, PatilS, and MisraA: Epidermal growth factor receptor targeting in cancer: A review of trends and strategies. Biomaterials, 2013; 34:8690–8707.
18.
HanazonoK, FukumotoS, KawamuraY, EndoY, KadosawaT, IwanoH, and UchideT: Epidermal growth factor receptor expression in canine transitional cell carcinoma. J Vet Med Sci, 2015; 77:1–6.
19.
BertagnolliAC, FerreiraE, DiasEJ, and CassaliGD: Canine mammary mixed tumours: Immunohistochemical expressions of EGFR and HER-2. Aust Vet J, 2011; 89:312–317.
20.
AraújoMR, CamposLC, DamascenoKA, GambaCO, FerreiraE, and CassaliGD: HER-2, EGFR, Cox-2 and Ki67 expression in lymph node metastasis of canine mammary carcinomas: Association with clinical-pathological parameters and overall survival. Res Vet Sci, 2016; 106:121–130.
21.
CarvalhoMI, GuimarãesMJ, PiresI, PradaJ, Silva-CarvalhoR, LopesC, and QueirogaFL: EGFR and microvessel density in canine malignant mammary tumours. Res Vet Sci, 2013; 95:1094–1099.
22.
GamaA, GärtnerF, AlvesA, and SchmittF: Immunohistochemical expression of epidermal growth factor receptor (EGFR) in canine mammary tissues. Res Vet Sci, 2009; 87:432–437.
23.
SabattiniS, ManciniFR, MarconatoL, BacciB, RossiF, VignoliM, and BettiniG: EGFR overexpression in canine primary lung cancer: Pathogenetic implications and impact on survival. Vet Comp Oncol, 2014; 12:237–248.
24.
ShiomitsuK, JohnsonCL, MalarkeyDE, PruittAF, and ThrallDE: Expression of epidermal growth factor receptor and vascular endothelial growth factor in malignant canine epithelial nasal tumours. Vet Comp Oncol, 2009; 7:106–114.
25.
SingerJ, WeichselbaumerM, StocknerT, MechtcheriakovaD, SobanovY, BajnaE, WrbaF, HorvatR, ThalhammerJG, WillmannM, and Jensen-JarolimE: Comparative oncology: ErbB-1 and ErbB-2 homologues in canine cancer are susceptible to cetuximab and trastuzumab targeting. Mol Immunol, 2012; 50:200–209.
26.
ItaiS, YamadaS, KanekoMK, ChangYW, HaradaH, and KatoY: Establishment of EMab-134, a sensitive and specific anti-epidermal growth factor receptor monoclonal antibody for detecting squamous cell carcinoma cells of the oral cavity. Monoclon Antib Immunodiagn Immunother, 2017; 36:272–281.
27.
HosonoH, TakeiJ, OhishiT, SanoM, AsanoT, SayamaY, NakamuraT, YanakaM, KawadaM, HaradaH, KanekoMK, and KatoY: Anti-EGFR monoclonal antibody 134-mG2a exerts antitumor effects in mouse xenograft models of oral squamous cell carcinoma. Int J Mol Med, 2020; 46:1443–1452.
OsakiT, SundenY, SugiyamaA, AzumaK, MurahataY, TsukaT, ItoN, ImagawaT, and OkamotoY: Establishment of a canine mammary gland tumor cell line and characterization of its miRNA expression. J Vet Sci, 2016; 17:385–390.
30.
KuwanoM, SonodaK, MurakamiY, WatariK, and OnoM: Overcoming drug resistance to receptor tyrosine kinase inhibitors: Learning from lung cancer. Pharmacol Ther, 2016; 161:97–110.
31.
GuardiolaS, VareseM, Sánchez-NavarroM, and GiraltE: A third shot at EGFR: New opportunities in cancer therapy. Trends Pharmacol Sci, 2019; 40:941–955.
32.
Van CutsemE, LenzHJ, KöhneCH, HeinemannV, TejparS, MelezínekI, BeierF, StrohC, RougierP, van KriekenJH, and CiardielloF: Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer. J Clin Oncol, 2015; 33:692–700.
33.
PeetersM, DouillardJY, Van CutsemE, SienaS, ZhangK, WilliamsR, and WiezorekJ: Mutant KRAS codon 12 and 13 alleles in patients with metastatic colorectal cancer: Assessment as prognostic and predictive biomarkers of response to panitumumab. J Clin Oncol, 2013; 31:759–765.
34.
López-AlbaiteroA, and FerrisRL: Immune activation by epidermal growth factor receptor specific monoclonal antibody therapy for head and neck cancer. Arch Otolaryngol Head Neck Surg, 2007; 133:1277–1281.
35.
DienstmannR, MarkmanB, and TaberneroJ: Application of monoclonal antibodies as cancer therapy in solid tumors. Curr Clin Pharmacol, 2012; 7:137–145.
36.
García-FoncillasJ, SunakawaY, AderkaD, WainbergZ, RongaP, WitzlerP, and StintzingS: Distinguishing features of cetuximab and panitumumab in colorectal cancer and other solid tumors. Front Oncol, 2019; 9:849.
37.
AllegraCJ, JessupJM, SomerfieldMR, HamiltonSR, HammondEH, HayesDF, McAllisterPK, MortonRF, and SchilskyRL: American Society of Clinical Oncology provisional clinical opinion: Testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol, 2009; 27:2091–2096.
38.
El GuerrabA, BamdadM, KwiatkowskiF, BignonYJ, Penault-LlorcaF, and AubelC: Anti-EGFR monoclonal antibodies and EGFR tyrosine kinase inhibitors as combination therapy for triple-negative breast cancer. Oncotarget, 2016; 7:73618–73637.
39.
SimonD, SchoenrockD, BaumgärtnerW, and NolteI: Postoperative adjuvant treatment of invasive malignant mammary gland tumors in dogs with doxorubicin and docetaxel. J Vet Intern Med, 2006; 20:1184–1190.
40.
HongM, ClubbJD, and ChenYY: Engineering CAR-T cells for next-generation cancer therapy. Cancer Cell, 2020; 38:473–488.
41.
YardenY: The EGFR family and its ligands in human cancer. Signalling mechanisms and therapeutic opportunities. Eur J Cancer, 2001; 37(Suppl. 4):S3–S8.
42.
SeungBJ, ChoSH, KimSH, LimHY, and SurJH: Quantitative analysis of HER2 mRNA expression by RNA in situ hybridization in canine mammary gland tumors: Comparison with immunohistochemistry analysis. PLoS One, 2020; 15:e0229031.
43.
TateyamaN, AsanoT, OhishiT, TakeiJ, HosonoH, NanamiyaR, TanakaT, SanoM, SaitoM, KawadaM, KanekoMK, and KatoY: An anti-HER2 monoclonal antibody H(2)Mab-41 exerts antitumor activities in mouse xenograft model using dog HER2-overexpressed cells. Monoclon Antib Immunodiagn Immunother, 2021; 40:184–190.
44.
SaccoAG, ChenR, WordenFP, WongDJL, AdkinsD, SwiecickiP, Chai-HoW, OppeltP, GhoshD, BykowskiJ, MolinoloA, PittmanE, EstradaMV, GoldK, DanielsG, LippmanSM, NatsuharaA, MesserK, and CohenEEW: Pembrolizumab plus cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma: An open-label, multi-arm, non-randomised, multicentre, phase 2 trial. Lancet Oncol, 2021; 22:883–892.
45.
DoroshowDB, BhallaS, BeasleyMB, ShollLM, KerrKM, GnjaticS, WistubaII, RimmDL, TsaoMS, and HirschFR: PD-L1 as a biomarker of response to immune-checkpoint inhibitors. Nat Rev Clin Oncol, 2021; 18:345–362.
46.
PanjwaniMK, SmithJB, SchutskyK, GnanandarajahJ, O'ConnorCM, PowellDJJr., and MasonNJ: Feasibility and safety of RNA-transfected CD20-specific chimeric antigen receptor T cells in dogs with spontaneous B cell lymphoma. Mol Ther, 2016; 24:1602–1614.
47.
LeBlancAK, and MazckoCN: Improving human cancer therapy through the evaluation of pet dogs. Nat Rev Cancer, 2020; 20:727–742.
48.
ParkJS, WithersSS, ModianoJF, KentMS, ChenM, LunaJI, CulpWTN, SpargerEE, RebhunRB, MonjazebAM, MurphyWJ, and CanterRJ: Canine cancer immunotherapy studies: Linking mouse and human. J Immunother Cancer, 2016; 4:97.
49.
DowS: A role for dogs in advancing cancer immunotherapy research. Front Immunol, 2019; 10:2935.
50.
CoyJ, CaldwellA, ChowL, GuthA, and DowS: PD-1 expression by canine T cells and functional effects of PD-1 blockade. Vet Comp Oncol, 2017; 15:1487–1502.
51.
PantelyushinS, RanningerE, GuerreraD, HutterG, MaakeC, MarkkanenE, Bettschart-WolfensbergerR, Rohrer BleyC, LäubliH, and Vom BergJ: Cross-reactivity and functionality of approved human immune checkpoint blockers in dogs. Cancers (Basel), 2021; 13:785.
52.
KlingemannH: Immunotherapy for dogs: Running behind humans. Front Immunol, 2018; 9:133.
